gilead.com

Website Review: gilead.com

 Generated on December 14 2022 00:39 AM

Old data? UPDATE !

The score is 56/100





SEO Content

Title

Gilead Sciences, Inc.

Length : 21

Your title's length should be between 40 and 70 characters. The optimal title length is between 50 to 70 chars. Use this meta tag generator to create a proper title tag.

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Length : 153

Great, your meta description tag's length is between 90 and 160 characters. A description tag of 155 to 160 characters is optimal.

Keywords

Not good (but low priority). We haven't found a meta keywords tag on your page. Use this free online meta tags generator to create a keywords tag.

Og Meta Properties

Good, your page takes advantage of Open Graph Properties. Open Graph properties can help with indexing.

Property Content
title Gilead Sciences, Inc.
description Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
image https://wwwam10.gilead.com/-/media/gilead-corporate/images/og/gilead_logo.jpg

Headings

H1 H2 H3 H4 H5 H6
1 7 4 3 1 0
  • [H1] World AIDS Day: Striving Together Toward Equity
  • [H2] Contact
  • [H2] Creating a Better Healthier World
  • [H2] Connecting Breast Cancer Education to Community: Equal Hope
  • [H2] Latinas Contra Cancer Empowers Patients to Advocate for Change
  • [H2] Tatiana Williams Leads the Way with the Transinclusive Group
  • [H2] Social
  • [H2] Headline
  • [H3] Advancing Global Health
  • [H3] Sustainability
  • [H3] Partnerships and Community
  • [H3] Recent Stories
  • [H4] Community
  • [H4] Community
  • [H4] Community
  • [H5] Recent News

Images

We found 16 images on this web page.

Awesome, most or all of your images have alt attributes. This helps search engines understand the content of your images.

Text/HTML Ratio

Ratio : 40%

Ideal! This page's ratio of text to HTML code is between 25 and 70 percent.

Flash

Perfect, no Flash content has been detected on this page.

Iframe

Not ideal - You have Iframes on the web page, this mean that content in an Iframe cannot be indexed.

URL Rewrite

Good. Your links look SEO friendly and are easy to crawl!

Underscores in the URLs

Great! No underscores found in your URLs.

In-page links

We found a total of 161 links including 1 link(s) to files

Anchor Type Juice
Medicine Questions External Passing Juice
Report an Adverse Event Internal Passing Juice
Investors Internal Passing Juice
Contact Internal Passing Juice
Canada External Passing Juice
Mexico Internal Passing Juice
USA Internal Passing Juice
Argentina Internal Passing Juice
Brazil Internal Passing Juice
China Mainland External Passing Juice
Hong Kong Internal Passing Juice
India Internal Passing Juice
Japan External Passing Juice
Korea External Passing Juice
Singapore Internal Passing Juice
Taiwan Internal Passing Juice
Israel External Passing Juice
Saudi Arabia Internal Passing Juice
Türkiye Internal Passing Juice
United Arab Emirates Internal Passing Juice
South Africa Internal Passing Juice
Australia and New Zealand Internal Passing Juice
Austria Internal Passing Juice
Belgium and Luxembourg External Passing Juice
Czech Republic & Slovakia Internal Passing Juice
Denmark Internal Passing Juice
Finland Internal Passing Juice
France External Passing Juice
Germany External Passing Juice
Greece Internal Passing Juice
Iceland Internal Passing Juice
Ireland Internal Passing Juice
Italy External Passing Juice
Netherlands Internal Passing Juice
Norway Internal Passing Juice
Poland & The Baltics Internal Passing Juice
Portugal Internal Passing Juice
Romania Internal Passing Juice
Russia Internal Passing Juice
Spain External Passing Juice
Sweden Internal Passing Juice
Switzerland Internal Passing Juice
United Kingdom External Passing Juice
Mission and Core Values Internal Passing Juice
Partnerships and Community Internal Passing Juice
Inclusion and Diversity Internal Passing Juice
Corporate Giving Internal Passing Juice
Gilead Foundation Internal Passing Juice
Sustainability Internal Passing Juice
Advancing Global Health Internal Passing Juice
Medication Access Internal Passing Juice
Leadership Internal Passing Juice
How We Operate Internal Passing Juice
Ethics and Code of Conduct Internal Passing Juice
Therapeutic Areas Internal Passing Juice
Medicines Internal Passing Juice
Pipeline Internal Passing Juice
Research Internal Passing Juice
Clinical Trials External Passing Juice
Events Internal Passing Juice
Stories Internal Passing Juice
Newsroom Internal Passing Juice
Company Statements Internal Passing Juice
Annual Reports Internal Passing Juice
Careers at Gilead Internal Passing Juice
Our Culture Internal Passing Juice
Meet Our Employees Internal Passing Juice
Inclusion and Diversity in Hiring Internal Passing Juice
Compensation, Benefits and Wellbeing Internal Passing Juice
Our Global Footprint Internal Passing Juice
Early Career Opportunities Internal Passing Juice
Postdoctoral Fellowships Internal Passing Juice
Hiring Events External Passing Juice
Talent Community Sign-up External Passing Juice
Privacy Statements Internal Passing Juice
Terms Of Use Internal Passing Juice
Social Media Guidelines Internal Passing Juice
EU Data Disclosure Internal Passing Juice
Sitemap Internal Passing Juice
BACK TO MAIN MENU Internal Passing Juice
COMPASS Initiative Internal Passing Juice
HepConnect Internal Passing Juice
HIV Age Positively Internal Passing Juice
Lift Internal Passing Juice
RADIAN Internal Passing Juice
TRANScend Internal Passing Juice
What We Fund Internal Passing Juice
Funding Requests Internal Passing Juice
Zeroing In: Ending the HIV Epidemic Internal Passing Juice
Creating Possible Fund Internal Passing Juice
Our Business Is Sustainable Internal Passing Juice
Performance Internal Passing Juice
Reporting Internal Passing Juice
U.N. Global Compact Internal Passing Juice
U.N. Sustainable Development Goals Internal Passing Juice
COVID-19 Internal Passing Juice
HCV Elimination Internal Passing Juice
U.S. Patient Access Internal Passing Juice
Disaster Product Replacement Internal Passing Juice
Global Access Internal Passing Juice
Authorized Distributors Internal Passing Juice
ESG Goals Internal Passing Juice
Governance Internal Passing Juice
Transparency Internal Passing Juice
Policies Internal Passing Juice
Anti-Bribery and Anti-Corruption Policy Internal Passing Juice
Animal Use and Welfare Policy Internal Passing Juice
Disclosures Internal Passing Juice
Anti-Counterfeiting Internal Passing Juice
Consumer Product Safety Internal Passing Juice
Supplier Information Internal Passing Juice
Political Engagement Internal Passing Juice
Research Scholars Program Internal Passing Juice
Compassionate Use Internal Passing Juice
Investigator-Sponsored Research Internal Passing Juice
Press Releases Internal Passing Juice
Media Inquiries Internal Passing Juice
Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Internal Passing Juice
Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Internal Passing Juice
Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Internal Passing Juice
Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Internal Passing Juice
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Internal Passing Juice
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade Internal Passing Juice
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Internal Passing Juice
Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Internal Passing Juice
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Internal Passing Juice
Gilead to Expand Footprint in Oceanside Internal Passing Juice
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Internal Passing Juice
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Internal Passing Juice
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Internal Passing Juice
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Internal Passing Juice
Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Internal Passing Juice
Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Internal Passing Juice
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Internal Passing Juice
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Internal Passing Juice
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Internal Passing Juice
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Internal Passing Juice
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Internal Passing Juice
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Internal Passing Juice
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Internal Passing Juice
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Internal Passing Juice
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Internal Passing Juice
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Internal Passing Juice
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Internal Passing Juice
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Internal Passing Juice
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Internal Passing Juice
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Internal Passing Juice
Gilead Sciences Statement on Recent Events in Washington, D.C. Internal Passing Juice
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Internal Passing Juice
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Internal Passing Juice
- Internal Passing Juice
- Internal Passing Juice
Year in Review 2021 Internal Passing Juice
Cookie Statement Internal Passing Juice
Partnership Request Internal Passing Juice
Gilead Sciences Again Named to Dow Jones Sustainability World Index Internal Passing Juice
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Internal Passing Juice
- External Passing Juice
Stories@Gilead Internal Passing Juice
Investor Calls Internal Passing Juice
Modern Slavery Act Statement Internal Passing Juice

SEO Keywords

Keywords Cloud

sciences      community      back      together      remdesivir      statement      main      gilead      hiv      menu     

Keywords Consistency

Keyword Content Title Keywords Description Headings
gilead 37
back 16
main 16
menu 16
statement 16

Usability

Url

Domain : gilead.com

Length : 10

Favicon

Great, your website has a favicon.

Printability

We could not find a Print-Friendly CSS.

Language

Good. Your declared language is en.

Dublin Core

This page does not take advantage of Dublin Core.

Document

Doctype

HTML 5

Encoding

Great. Your declared charset is UTF-8.

W3C Validity

Errors : 12

Warnings : 15

Email Privacy

Warning! At least one email address has been found in plain text. Consider using an image or a form to hide email from spammers.

Deprecated HTML

Great! We haven't found deprecated HTML tags in your HTML.

Speed Tips

Excellent, your website doesn't use nested tables.
Not great, your website is using inline styles. This is not optimal.
Great, your website has few CSS files.
This website has an excessive amount of Javascript files (more than 6).
Awesome, your website takes advantage of GZIP compression for SEO optimization.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Optimization

XML Sitemap

Missing

Your website does not have an XML sitemap - this can be a problem for search engines.

An XML sitemap informs search engines about URLs available for crawling on your site. It includes information about your site's latest updates, frequency of changes and relative importance of each URL. This allows search engines to crawl the site more efficiently.

Robots.txt

http://gilead.com/robots.txt

Great, your website has a robots.txt file.

Analytics

Missing

Unverified

PageSpeed Insights

Device
Categories

Website Review

Website Review is a free SEO site review and rating tool. Get a free review of your site and see areas that may need optimization.